IVEVF News and Press, Inventiva

Daix (France), New York (United States), February 26, 2026  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabo...

Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits 2 as of December 31, 2025 Revenues of €4.5 million in 2025 Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million 3 ) Cash ru...

Daix (France), New York (United States), February 4, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metaboli...

2026-01-15 14:16:01 ET Inventiva S.A. (IVA) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Inventiva S.A. (IVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Daix (France), New York City (New York, United States), December 17, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treat...

Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associa...

2025-11-24 07:48:23 ET More on Inventiva S.A Inventiva S.A. (IVA) Analyst/Investor Day - Slideshow Inventiva S.A. (IVA) Analyst/Investor Day Transcript Inventiva announces $125M U.S. public offering of ADSs MASH drug developers rise as FDA accepts lenient tri...

Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits 2 as of September 30, 2025. Revenues of €4.5 million for the first nine months of 2025. Cash runway expected until the end of the first quarter of 2027 3 , including net proce...

Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfun...

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfun...